Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00090038 · ClinicalTrials.gov registry record · Phase 4
Effect of Rituximab on Immunological Recall Response to Specific Antigens in the Treatment of Non-Hodgkin's Lymphoma
A Phase 4 study, sponsored by Biogen.
- Completed
- Registry status
- Phase 4
- Development phase
- 168
- Enrollment target
NCT00090038 is a Phase 4 study that has completed, run by Biogen. The registered enrollment target is 168 participants.
The verdict
NCT00090038, a Phase 4 study, has completed, sponsored by Biogen.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 168 participants
- Enrollment target
Study Summary
The purpose of this study is to provide treatment for patients who have relapsed Non-Hodgkin's lymphoma (NHL) or refractory NHL, and to test the immunity of study subjects after receiving four treatments with rituximab.
Interventions
- DRUG rituximab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 168 participants |
| Start Date | 2003-10 |
| Est. Completion | 2007-11 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00090038
The ClinicalTrials.gov registry entry for NCT00090038 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 168 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biogen, which has 334 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which rituximab is the first listed.
NCT00090038 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00090038 about?
NCT00090038 is a clinical study titled "Effect of Rituximab on Immunological Recall Response to Specific Antigens in the Treatment of Non-Hodgkin's Lymphoma". The purpose of this study is to provide treatment for patients who have relapsed Non-Hodgkin's lymphoma (NHL) or refractory NHL, and to test the immunity of study subjects after receiving four treatments with rituximab.
What is the current status of trial NCT00090038?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 168 participants. The study started on 2003-10. Estimated completion is 2007-11.
What interventions are being tested in trial NCT00090038?
The interventions under investigation include: rituximab (DRUG).
Who is sponsoring clinical trial NCT00090038?
This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.